Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor
Authors:
- Isabelle FajacIFIsabelle Fajac
- Cori DainesCDCori Daines
- Isabelle DurieuIDIsabelle Durieu
- Jennifer L. GoralskiJGJennifer L. Goralski
- Harry HeijermanHarry Heijerman
- Christiane KnoopCKChristiane Knoop
- Bote G. BruinsmaBBBote G. Bruinsma
- Samuel MoskowitzSMSamuel Moskowitz
- Valentin Prieto-CenturionVPValentin Prieto-Centurion
- Kate Van BruntKBKate Van Brunt
- Yaohua ZhangYZYaohua Zhang
Open Access
- 14 September 2022
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (1) , 119-123
Abstract
No abstract availableKeywords
Funding Information
- Vertex Pharmaceuticals Incorporated
This publication has 10 references indexed in Scilit:
- Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialThe Lancet Respiratory Medicine, 2022
- Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosisInternational Forum of Allergy & Rhinology, 2020
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delNew England Journal of Medicine, 2017
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Longitudinal Trends in Health-Related Quality of Life in Adults With Cystic FibrosisChest, 2013
- Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sampleQuality of Life Research, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Longitudinal assessment of health‐related quality of life in an observational cohort of patients with cystic fibrosisPediatric Pulmonology, 2010